Esperion Therapeutics ESPR 深 滬
等待開盤 10-17 09:30:00 美东时间
2.625
+0.105
+4.17%
華盛通- 最 高2.66
- 今 開2.53
- 成交量 343.13万股
- 最 低 2.5204
- 昨 收 2.52
- 總市值 5.30亿
- 52周最高 3.94
- 市盈率 靜 --
- 換手率 1.70%
- 52周最低 0.6925
- 委 比 33.48%
- 總股本 2.02亿
- 歷史最高 120.96
- 量 比 0.55
- 振 幅 5.54%
- 歷史最低 0.6925
- 每 手 1
- 風險率 0.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
Esperion announced the nomination of ESP-2001, a highly-specific allosteric ACLY inhibitor for the treatment of primary sclerosing cholangitis (PSC), targeting liver and bile duct injury, inflammation, and fibrosis. Preclinical data suggest ESP-2001 may significantly impact PSC progression, a disease with no approved treatments. The company plans to advance ESP-2001 through IND-enabling studies, aiming to file an IND with the FDA in 2025 and begi...
10-16 12:00
Dow Jumps Over 100 Points; US Crude Oil Inventories Increase
U.S. stocks traded higher midway through trading, with the Dow Jones index gain...
10-09 01:22
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
10-09 01:06
Esperion Therapeutics prices $75M public offering
Esperion Therapeutics (ESPR) is offering 30M shares of common stock at $2.50 per share in an underwritten public offering. The company has granted underwriters a 30-day option to purchase up to 4.5M a...
10-08 13:34
Esperion slides after pricing $75M stock offering
Esperion Therapeutics (NASDAQ:ESPR) priced an underwritten public offering of 30M shares at $2.50 each, aiming to raise about $75M in gross proceeds. Underwriters have a 30-day option to buy up to 4.5...
10-08 13:24
Esperion Announces Pricing of Public Offering of Common Stock
Esperion Therapeutics, a biopharmaceutical company, has announced the pricing of an underwritten public offering of 30 million shares of its common stock at $2.50 per share, expecting to raise approximately $75 million. The offering, which includes a 30-day option for underwriters to purchase an additional 4.5 million shares, is set to close on October 9, 2025. Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book-running manag...
10-08 01:29
Esperion, Dr. Reddy's Laboratories Reach Patent Dispute Settlement; Dr. Reddy's Agrees Not To Market NEXLETOL Or NEXLIZET In US Before 2040
ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. and its affiliate Dr. Reddy's Laboratories
10-03 20:04
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Esperion announced that its partner, Otsuka Pharmaceutical, has received approval in Japan to market NEXLETOL for hypercholesterolemia and familial hypercholesterolemia. This marks a major milestone in Esperion's international growth strategy, as Japan is one of the top three global markets for cardiovascular prevention. With NEXLETOL now approved in the U.S., Europe, and Japan, Esperion has expanded access to its non-statin LDL-C lowering therap...
09-19 12:00
Espey Mfg. & Electronics Corp. reports fourth quarter and year-end results
Espey Mfg. & Electronics Corp. reported fiscal year 2025 net sales of $43.95 million, up 13% from $38.74 million in 2024, with net income rising 39% to $8.14 million ($3.02 per diluted share) from $5.82 million ($2.29 per diluted share). Fourth quarter 2025 net sales were $9.60 million versus $11.61 million last year, with net income up 55% to $2.93 million ($1.05 per diluted share) from $1.89 million ($0.73 per diluted share). The company ended ...
09-16 20:05
